Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by AXS Investments LLC

AXS Investments LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,706 shares of the medical research company’s stock after purchasing an additional 144 shares during the quarter. AXS Investments LLC’s holdings in Thermo Fisher Scientific were worth $1,967,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in TMO. FineMark National Bank & Trust increased its stake in Thermo Fisher Scientific by 2.1% during the fourth quarter. FineMark National Bank & Trust now owns 22,069 shares of the medical research company’s stock worth $11,714,000 after acquiring an additional 447 shares during the last quarter. Frazier Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $49,000. Seven Mile Advisory acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $246,000. Journey Strategic Wealth LLC increased its stake in Thermo Fisher Scientific by 16.1% during the fourth quarter. Journey Strategic Wealth LLC now owns 1,929 shares of the medical research company’s stock worth $1,024,000 after acquiring an additional 268 shares during the last quarter. Finally, Aigen Investment Management LP boosted its position in shares of Thermo Fisher Scientific by 105.8% in the fourth quarter. Aigen Investment Management LP now owns 4,442 shares of the medical research company’s stock worth $2,358,000 after buying an additional 2,284 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $5.77 on Thursday, reaching $585.03. 1,167,331 shares of the company were exchanged, compared to its average volume of 1,504,295. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company’s 50-day moving average is $576.44 and its two-hundred day moving average is $545.71. The firm has a market cap of $223.32 billion, a price-to-earnings ratio of 37.90, a P/E/G ratio of 2.75 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TMO. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. JPMorgan Chase & Co. upped their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Barclays upped their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. Raymond James increased their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Finally, HSBC increased their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $607.35.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold a total of 32,000 shares of company stock worth $18,486,980 in the last three months. 0.34% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.